• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

Professional Introduction to 4-Bromo-5-chloro-2-nitrobenzoic acid (CAS No. 1437795-19-1)

4-Bromo-5-chloro-2-nitrobenzoic acid, identified by its Chemical Abstracts Service (CAS) number 1437795-19-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This benzoic acid derivative features a unique structural configuration, incorporating bromine and chlorine substituents alongside a nitro group, which endows it with distinct chemical properties and reactivity patterns. The compound’s molecular structure, characterized by its aromatic ring system, makes it a valuable intermediate in synthetic chemistry, particularly in the development of biologically active molecules.

The significance of 4-Bromo-5-chloro-2-nitrobenzoic acid lies in its utility as a building block for more complex pharmacophores. Its halogenated nitrobenzoic acid framework provides a versatile platform for further functionalization, enabling chemists to explore modifications that can enhance binding affinity, metabolic stability, and other pharmacokinetic profiles. In recent years, there has been growing interest in such halogenated nitroaromatic compounds due to their role in modulating various biological pathways.

One of the most compelling aspects of 4-Bromo-5-chloro-2-nitrobenzoic acid is its application in the synthesis of novel therapeutic agents. Researchers have leveraged its structural features to develop molecules with potential applications in oncology, immunology, and anti-inflammatory treatments. For instance, studies have demonstrated that derivatives of this compound can interact with specific enzymes and receptors, influencing cellular signaling cascades that are dysregulated in diseases such as cancer.

Recent advancements in computational chemistry have further highlighted the importance of 4-Bromo-5-chloro-2-nitrobenzoic acid as a scaffold for drug discovery. Molecular modeling techniques have been employed to predict how modifications to its structure can optimize interactions with biological targets. These virtual screening approaches have accelerated the identification of lead compounds that could undergo further optimization into viable drug candidates.

The synthesis of 4-Bromo-5-chloro-2-nitrobenzoic acid itself is a testament to the ingenuity of synthetic organic chemists. The process typically involves multi-step reactions starting from commercially available precursors such as bromobenzene or chlorobenzene derivatives. Nitration followed by selective halogenation yields the desired product, showcasing the compound’s synthetic accessibility while maintaining high purity standards essential for pharmaceutical applications.

In clinical research, 4-Bromo-5-chloro-2-nitrobenzoic acid has been explored for its potential as an anti-cancer agent. Preclinical studies indicate that certain analogs derived from this compound exhibit inhibitory effects on kinases and other enzymes implicated in tumor growth and progression. The presence of bromine and chlorine atoms enhances lipophilicity, which can improve membrane permeability and target specificity—a critical factor in drug design.

The pharmacological profile of 4-Bromo-5-chloro-2-nitrobenzoic acid is further illuminated by its interaction with biological systems. Researchers have investigated its effects on oxidative stress pathways, finding that it can modulate reactive oxygen species (ROS) levels within cells. This has implications for diseases where oxidative damage plays a significant role, such as neurodegenerative disorders and cardiovascular conditions.

From an industrial perspective, the demand for 4-Bromo-5-chloro-2-nitrobenzoic acid continues to rise as pharmaceutical companies seek innovative solutions for drug development. Its role as an intermediate not only simplifies synthetic routes but also reduces costs associated with multi-step syntheses. This economic efficiency makes it an attractive choice for large-scale production where scalability and reproducibility are paramount.

The environmental impact of producing and utilizing 4-Bromo-5-chloro-2-nitrobenzoic acid is also a consideration in modern research practices. Efforts are underway to develop greener synthetic methodologies that minimize waste and hazardous byproducts. These sustainable approaches align with broader industry goals to reduce the ecological footprint of chemical manufacturing while maintaining high-quality output.

In summary, 4-Bromo-5-chloro-2-nitrobenzoic acid (CAS No. 1437795-19-1) represents a cornerstone in medicinal chemistry due to its structural versatility and functional utility. Its contributions to drug discovery continue to evolve with advancements in synthetic techniques and computational methods, positioning it as a key player in the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)